Soluble immune checkpoints in endometrial cancer – a discovery study
Although soluble immune checkpoint levels did not differentiate EC patients from controls, several sICs correlated with key prognostic and predictive features, including LVSI, advanced stage, and MMR deficiency. These findings suggest that circulating immune checkpoint proteins may serve as non-invasive biomarkers for risk assessment and immunotherapy response prediction in endometrial cancer. Further validation in larger, independent cohorts is warranted.
Authors
- Luka Roškar (ORCID: https://orcid.org/0000-0001-9692-7043)
- Maja Pušić (ORCID: https://orcid.org/0000-0003-0458-7729)
- Boštjan Pirš (ORCID: https://orcid.org/0000-0002-6153-1978)
- Špela Smrkolj (ORCID: https://orcid.org/0000-0001-9698-2130)
- Tea Lanišnik Rižner (ORCID: https://orcid.org/0000-0002-3453-4081)
Institutions
- University of Ljubljana (SI)
- Ljubljana University Medical Centre (SI)
- Pomurski muzej Murska Sobota (SI)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-21
- DOI
- https://doi.org/10.3389/fimmu.2025.1721822
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Javna Agencija za Raziskovalno Dejavnost RS